Viking Therapeutics Takeover Target in Biotech Investing?
Investors increasingly ask whether Viking Therapeutics could become a takeover target. This article breaks down why b...
Index funds win long term largely because of lower costs and broad diversification. This brief introduces the cost advantage and payoff.
27,987 articlesInvestors increasingly ask whether Viking Therapeutics could become a takeover target. This article breaks down why b...
Nvidia is facing a mixed start to 2026, but the long-term case remains intact. This article explains why a 40% jump b...
A fresh wave of AI-driven momentum is reshaping Amazon's outlook, and investors are paying close attention. This arti...
The YieldMax MSFT Option Income Strategy ETF (MSFO) continues to lure income-seeking investors with weekly payouts, b...
This deep dive breaks down NCDLs Q1 2026 performance, translates what the ncdl 2026 earnings call hinted at, and show...
A wave of XRP buyers is pushing long bets higher across venues, but a troubling metric shows risk to a sustained rall...
JPMorgan Chase has built a long runway of dividend growth, but is it the best dividend stock in banking for your port...
A 64-year-old executive faces a year of severance after a sudden layoff and chooses to claim Social Security at 64. T...
Caterpillar—a 100-year-old icon in heavy equipment—is redefining its path by embracing AI-enabled infrastructure, dat...
A hedge fund quietly pulled the plug on a sizable Cinemark stake after a sharp stock decline. The move, disclosed in ...
Netflix backed away from a Warner Bros. deal, signaling a calculated shift in strategy. Here are five practical reaso...
SpaceX is hovering around its $135 IPO price as investors digest post-debut dynamics. One broker, Raymond James, argu...